KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $2.8 million.

  • Aquestive Therapeutics' Share-based Compensation rose 7609.38% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 5349.54%. This contributed to the annual value of $7.1 million for FY2024, which is 16400.15% up from last year.
  • Aquestive Therapeutics' Share-based Compensation amounted to $2.8 million in Q3 2025, which was up 7609.38% from $1.9 million recorded in Q2 2025.
  • Aquestive Therapeutics' Share-based Compensation's 5-year high stood at $2.8 million during Q3 2025, with a 5-year trough of $344000.0 in Q1 2023.
  • Over the past 5 years, Aquestive Therapeutics' median Share-based Compensation value was $1.6 million (recorded in 2024), while the average stood at $1.4 million.
  • In the last 5 years, Aquestive Therapeutics' Share-based Compensation crashed by 7184.21% in 2022 and then skyrocketed by 35930.23% in 2024.
  • Aquestive Therapeutics' Share-based Compensation (Quarter) stood at $1.7 million in 2021, then plummeted by 57.78% to $714000.0 in 2022, then surged by 31.65% to $940000.0 in 2023, then skyrocketed by 155.64% to $2.4 million in 2024, then increased by 15.56% to $2.8 million in 2025.
  • Its Share-based Compensation stands at $2.8 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.6 million for Q1 2025.